Thelansis

Neuromyelitis Optica (NMO) Market Outlook Thelansis’s “Neuromyelitis Optica (NMO) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Neuromyelitis Optica (NMO) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market...

Neuromyelitis Optica (NMO) Market Outlook Thelansis’s “Neuromyelitis Optica (NMO) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Neuromyelitis Optica (NMO) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Neuromyelitis Optica (NMO) Overview Neuromyelitis optica (NMO), also known as Devic syndrome, manifests as a clinical syndrome characterized by recurrent acute optic neuritis and transverse myelitis. In the majority of patients, NMO is driven by pathogenic serum IgG autoantibodies targeting aquaporin 4 (AQP4), which happens to be the most prevalent water-channel protein within the central nervous system (CNS). In more than 80%...

 Neuromyelitis optica (NMO), also known as Devic syndrome, manifests as a clinical syndrome characterized by recurrent acute optic neuritis and transverse myelitis. In the majority of patients, NMO is driven by pathogenic serum IgG autoantibodies targeting aquaporin 4 (AQP4), which happens to be the most prevalent water-channel protein within the central nervous system (CNS). In more than 80% of cases, NMO is a result of the presence of pathogenic IgG autoantibodies directed against aquaporin 4 (AQP4-IgG), the predominant water channel protein in the CNS. Roughly 10–40% of individuals diagnosed with NMO who do not possess AQP4-IgG instead have IgG autoantibodies targeting myelin oligodendrocyte glycoprotein (MOG-IgG). Notably, MOG-IgG is also detected in a subgroup of patients, primarily children, with acute disseminated encephalomyelitis (ADEM). The most prominent risk factor for NMO is gender, with a strong association observed in females, particularly in those with AQP4-IgG-posi...